InflaRx NVIFRX +2.13%31 3-Year ROIIC % is 385.60 as of Dec. 2025. GuruFocus rates IFRX with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 1,320 Biotechnology companies, InflaRx NV ranks better than 89.32% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
InflaRx NV's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 385.60%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for InflaRx NV's 3-Year ROIIC % or its related term are showing as below:
IFRX's 3-Year ROIIC % is ranked better than 89.32% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs IFRX: 385.60
InflaRx NV (NAS:IFRX) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
InflaRx NV 3-Year ROIIC % Related Terms
InflaRx NV 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for InflaRx NV's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IFRX vs BCYC, ELDN, ZNTL: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, InflaRx NV's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InflaRx NV 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InflaRx NV's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where InflaRx NV's 3-Year ROIIC % falls into.
InflaRx NV's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -56.507 (Dec. 2025) - -34.15 (Dec. 2022) )
/
( 10.732 (Dec. 2025) - 16.53 (Dec. 2022) )
=
-22.357
/
-5.798
=
385.60%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
InflaRx NV (IFRX) has a 3-Year ROIIC % of 385.60 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on InflaRx NV and its competitors. According to the industry distribution chart, InflaRx NV ranks #141 out of 1320 companies in the Biotechnology industry, placing it in the top 10.7%.
Is InflaRx NV's 3-Year ROIIC % too high?
InflaRx NV's current 3-Year ROIIC % is 385.60. Based on the distribution chart, InflaRx NV ranks #141 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, InflaRx NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's 3-Year ROIIC % compare to BCYC and ELDN?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #141 out of 1320 companies for 3-Year ROIIC %. This places InflaRx NV in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on InflaRx NV and its competitors. InflaRx NV's current 3-Year ROIIC % is 385.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (IFRX) has a current 3-Year ROIIC % of 385.60. The current 3-Year ROIIC % is 385.60. InflaRx NV's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For InflaRx NV (IFRX), the current 3-Year ROIIC % is 385.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
31GF Score
Get the complete analysis for IFRX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IFRX has been successfully added to your 
